JOHN J ORLOFF
CIK 1643941 · EVP, Research & Development · last filed 2025-06-12
JOHN J ORLOFF is an EVP, Research & Development who has filed 21 SEC Form 4 insider transactions across 3 companies since 2015. The most recent filing, for ZBIO, was dated Jun 12, 2025.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
3
21
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZBIO | Director | — | $19.80 | — | $0 | 2 | 2025-06-12 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | See Remarks | — | — | — | $0 | 3 | 2018-08-13 |
| Baxalta Inc (BXLT) Delisted | EVP and President, R&D | 96,009 | — | — | $0 | 2 | 2016-03-07 |
Recent Filings
21 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-12 | ZBIO | Grant (A) | — | $0 | EDGAR |
| 2024-09-16 | ZBIO | Grant (A) | — | $0 | EDGAR |
| 2021-07-23 | — | Disp (D) | −146,511 | $0 | |
| 2021-07-16 | — | Grant (A) | +60,144 | $0 | |
| 2021-06-09 | — | Tax (F) | −1,957 | -$346.4K | |
| 2021-03-02 | — | Grant (A) | +24,473 | $0 | |
| 2020-12-18 | — | Mixed | +19,322 | -$3.38M | |
| 2020-06-09 | — | Tax (F) | −2,784 | -$319.1K | |
| 2020-03-03 | — | Mixed | +9,522 | -$122.8K | |
| 2019-06-11 | — | Tax (F) | −2,786 | -$330.4K |